GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: Avonex® | Rebif®
IFN-β1a (recombinant human) is an approved drug (FDA (1996), EMA (1997))
Compound class:
Peptide
Comment: Compared to the sequence of the endogenous peptide, IFN-β1a has a Gln to Cys substitution at position 17 and retains the Asn glycosylation site at position 80. Whilst the regular form of this peptide has to be injected 1-3 times/week, a PEGylated form (peginterferon beta-1a) is now available that requires less frequent administration (on a fortnightly basis).
|
